drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor that targets BAFFR (TNFRSF13C) on malignant B cells, leading to T-cell activation and cytotoxic killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor that binds BAFFR (TNFRSF13C) on malignant B cells; CAR engagement triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BAFFR-expressing B cells.
drug_name
Autologous BAFFR-targeting CAR T Cells (MC10029)
nct_id_drug_ref
NCT06191887